Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Post by SABBOBCATon Oct 17, 2019 12:08pm
159 Views
Post# 30240253

"Shortly"

"Shortly"

“We will shortly request a meeting with the FDA and the EMA to ascertain the phase III clinical trial approach required to obtain approval of tesamorelin for the 2 treatment in NAFLD/NASH"

What I am hoping we get out of Oct 2,3 at the very least, is a more definitive timeline. As we have experienced, management’s expectations may not be as aggressive as our own so I would like to better understand their definition of “shortly”.

I am not experienced in the FDA processes, so in looking at the FDA's Guidance for Industry: Formal Meetings Between the FDA and Sponsors or Applicants, I would assume THTX will request a “Type B (EOP) Meeting”. For this type, the meeting request response time is 14 days and then the meeting scheduling time frame is 70 days.

So if the FDA processes take about 3 months, how long will it take management to get the meeting request package together? Is 4-6 weeks a safe assumption? This would put us at late Feb or early March if there are delays during the holiday season.

Given the history of delays with THTX, I won’t hold my breath. All we can do is hurry up and wait.  

Bullboard Posts